Severe contact esophagitis in a patient taking crizotinib: A case report

Asia-Pacific Journal of Clinical Oncology

Volumn 11, Issue 2, 2015, Pages 187-189

  Conduit, Ciara ^a   Wilson, Mark ^a   Hunter, Karen ^a   Murdolo, Vince ^a   Nott, Louise ^a  

^a ROYAL HOBART HOSPITAL   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

ANAPLASTIC LYMPHOMA KINASE; CARBOPLATIN; CRIZOTINIB; DEXAMETHASONE; ESOMEPRAZOLE; KETAMINE; LIDOCAINE; MYLANTA; NAVELBINE; OPIATE; PEMETREXED; RANITIDINE; PYRAZOLE DERIVATIVE; PYRIDINE DERIVATIVE;

ADULT; ADVANCED CANCER; ARTICLE; BRAIN EDEMA; BRAIN METASTASIS; BRAIN RADIATION; CANCER RADIOTHERAPY; CASE REPORT; COMPUTER ASSISTED TOMOGRAPHY; DRUG SUBSTITUTION; DRUG WITHDRAWAL; ESOPHAGITIS; EVENING DOSAGE; FEMALE; GASTROESOPHAGEAL REFLUX; GASTROSCOPY; GENE REARRANGEMENT; HOSPITALIZATION; HUMAN; MIDDLE AGED; NON SMALL CELL LUNG CANCER; NOSE FEEDING; ODYNOPHAGIA; PRIORITY JOURNAL; TREATMENT RESPONSE; WEIGHT REDUCTION;

ESOPHAGITIS; FEMALE; HUMANS; MIDDLE AGED; PYRAZOLES; PYRIDINES;

EID: 84928825032     PISSN: 17437555     EISSN: 17437563     Source Type: Journal    
DOI: 10.1111/ajco.12341     Document Type: Article

References (10)

1. Shaw A, Kim D, Nakagawa K etal. Crizotinib versus chemotherapy in advanced ALK-Positive lung cancer. N Engl J Med 2013; 368 (25): 2385-2394.
2. Shaw A, Solomon B. Anaplastic lymphoma kinase (ALK) fusion oncogene positive non-small cell lung cancer. In: Ross M (ed). UpToDate. UpToDate, Waltham, MA 2014.
3. Camidge D, Bang Y, Kwak E etal. Activity and safety of crizotinib in patients with ALK-positive on-small-cell-lung cancer: updated results from a phase 1 study. Lancet Oncol 2012; 13 (13): 1011-1018.
4. Kim D, Bang Y, Kwak E etal. Results of a global phase II study with crizotinib in advanced ALK-positive non-small cell lung cancer (NSCLC). The Annual Meeting of the American Society of Clinical Oncology; Chicago 2012.
5. Park J, Yoshida K, Kondo C, Shimizu J, Hotio Y, Hida T. Crizotinib-induced esophageal ulceration: a novel adverse event of crizotinib. Lung Cancer 2013; 81 (3): 495-496.
6. Jalil A, Craig J, Bajaj R, Spurling T. Severe ulcerative esophagitis induced by crizotinib therapy. ACG Case Rep J 2014; 1 (2): 82-84.
7. Takakuwa O, Oguri T, Yokoyama M etal. Esophagitis resulting from treatment with crizotinib for anaplastic lymphoma kinase rearrangement-positive lung adenocarcinoma: a case report. Mol Clin Oncol 2014; 2: 121-123.
8. Srivastava N, VanderLaan P, Kelly C, Costa D. Esophagitis: a novel adverse event of crizotinib in a patient with ALK-Positive Non-Small-Cell lung cancer. J Thorac Oncol 2013; 8 (3): c23-24.
9. O'Castell D. Medication-induced esophagitis. In: LaMont J (ed). UpToDate. UpToDate, Waltham, MA 2012.
10. Electronic Medicines Compendium. Xalkori 200mg and 250mg hard capsule. 2014. [cited 11 August 2014]. Available from URL: http://www.medicines.org.uk/emc/medicine/27168.